Tomorrow GOVX presents (COVID-19) update
During his second presentation on March 4, entitled Development of Single Dose Vaccines for Emerging Infectious Diseases Using a Novel MVA Platform, Dr. Guirakhoo will discuss the Company’s design of MVA-VLP and non-VLP vaccines for Zika, Ebola, Marburg and Lassa fever vaccines, as well as results from efficacy studies in animal challenge models. During this presentation, Dr. Guirakhoo also expects to give a current update on the Company’s collaboration with BravoVax, based in Wuhan, China, on use of GeoVax’s vaccine technology platform and expertise to develop a vaccine for prevention/control of the novel coronavirus disease (COVID-19).
